Addex Therapeutics Ltd. (NASDAQ:ADXN)
| Market Cap | $4.27M-52.5% |
| Revenue (ttm) | $47.57K-48.1% |
| Net Income | -$6.86M-13.5% |
| EPS | -$5.60+25.8% |
| Shares Out | 1.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,218 |
| Open | $3.25 |
| Previous Close | $3.40 |
| Day's Range | $3.25 - $3.53 |
| 52-Week Range | $2.56 - $10.43 |
| Beta | 2.07 |
| Analysts | Buy |
| Price Target | $30.00(+764.55%) |
| Earnings Date | n/a |
About ADXN
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
$ADXN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ADXN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ADXN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ADXN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ADXN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ADXN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ADXN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Addex's spinout Neurosterix successfully closed $105M Series B financing, demonstrating investor confidence and de-risking the pipeline.
